CTOs on the Move

Kaleido Biosciences

www.kaleido.com

 
Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome`s ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.kaleido.com
  • 18 Crosby Drive
    Bedford, MA USA 01730
  • Phone: 617.674.9000

Executives

Name Title Contact Details
Stephen Sofen
Senior Vice President of Technical Operation Profile

Funding

Kaleido Biosciences raised $60.4M on 02/04/2021

Similar Companies

Expertec Dental Lab Inc

Expertec Dental Lab Inc is a Westland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inter Science Institute

Inter Science Institute is a Inglewood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calloway Labs

Calloway Labs is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kollsut Scientific Corporation

Kollsut Scientific Corporation is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zai Lab

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. We are further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year. Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. To that end, we have built our internal R&D center to advance our discovery pipeline, a strong clinical development and operations team, and our own manufacturing facilities in China. We have also established a highly specialized commercial team to support marketing of our innovative products in China. We believe this integrated approach will provide sustainable competitive advantages for Zai Lab. Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017. Since then, Zai Lab significantly expanded with several offices across China and opened its U.S. headquarters in San Francisco in December 2018. As of December 2019, the Company has a global team of approximately 700 employees.